Literature DB >> 19201360

Differentiation of common large sellar-suprasellar masses effect of artificial neural network on radiologists' diagnosis performance.

Mika Kitajima1, Toshinori Hirai, Shigehiko Katsuragawa, Tomoko Okuda, Hirofumi Fukuoka, Akira Sasao, Masuma Akter, Kazuo Awai, Yoshiharu Nakayama, Ryuji Ikeda, Yasuyuki Yamashita, Shigetoshi Yano, Jun-ichi Kuratsu, Kunio Doi.   

Abstract

RATIONALE AND
OBJECTIVES: When pituitary adenoma, craniopharyngioma, and Rathke's cleft cyst grow in the sellar and suprasellar region, it is often difficult to differentiate among these three lesions on magnetic resonance (MR) images. The purpose of this study was to apply an artificial neural network (ANN) for differential diagnosis among these three lesions with MR images and retrospectively evaluate the effect of ANN output on radiologists' performance.
MATERIALS AND METHODS: Forty-three patients with sellar-suprasellar masses were studied. The ANN was designed to differentiate among pituitary adenoma, craniopharyngioma, and Rathke's cleft cyst by using patients' ages and nine MR image findings obtained by three neuroradiologists using a subjective rating scale. In the observer performance test, MR images were viewed by nine radiologists, including four neuroradiologists and five general radiologists, first without and then with ANN output. The radiologists' performance was evaluated using receiver-operating characteristic analysis with a continuous rating scale.
RESULTS: The ANN showed high performance in differentiation among the three lesions (area under the receiver-operating characteristic curve, 0.990). The average area under the curve for all radiologists for differentiation among the three lesions increased significantly from 0.910 to 0.985 (P = .0024) when they used the computer output. Areas under the curves for the general radiologists and neuroradiologists increased from 0.876 to 0.983 (P = .0083) and from 0.952 to 0.989 (P = .038), respectively.
CONCLUSION: In diagnostic performance for differentiation among pituitary macroadenoma, craniopharyngioma, and Rathke's cleft cyst with MR imaging, the ANN resulted in parity between neuroradiologists and general radiologists.

Entities:  

Mesh:

Year:  2009        PMID: 19201360     DOI: 10.1016/j.acra.2008.09.015

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  7 in total

1.  Fluid-fluid level on magnetic resonance images may predict the occurrence of pituitary adenomas in cystic sellar-suprasellar masses.

Authors:  Deyong Xiao; Shousen Wang; Lin Zhao; Qun Zhong; Yinxing Huang; Chenyu Ding
Journal:  Exp Ther Med       Date:  2017-04-04       Impact factor: 2.447

2.  A Brief History of Machine Learning in Neurosurgery.

Authors:  Andrew T Schilling; Pavan P Shah; James Feghali; Adrian E Jimenez; Tej D Azad
Journal:  Acta Neurochir Suppl       Date:  2022

Review 3.  Machine Learning in Pituitary Surgery.

Authors:  Vittorio Stumpo; Victor E Staartjes; Luca Regli; Carlo Serra
Journal:  Acta Neurochir Suppl       Date:  2022

Review 4.  Application of artificial intelligence and radiomics in pituitary neuroendocrine and sellar tumors: a quantitative and qualitative synthesis.

Authors:  Kelvin Koong; Veronica Preda; Anne Jian; Benoit Liquet-Weiland; Antonio Di Ieva
Journal:  Neuroradiology       Date:  2021-11-27       Impact factor: 2.804

5.  A systematic review on machine learning in sellar region diseases: quality and reporting items.

Authors:  Nidan Qiao
Journal:  Endocr Connect       Date:  2019-07       Impact factor: 3.335

6.  Automatic diagnosis of neurological diseases using MEG signals with a deep neural network.

Authors:  Jo Aoe; Ryohei Fukuma; Takufumi Yanagisawa; Tatsuya Harada; Masataka Tanaka; Maki Kobayashi; You Inoue; Shota Yamamoto; Yuichiro Ohnishi; Haruhiko Kishima
Journal:  Sci Rep       Date:  2019-03-25       Impact factor: 4.379

Review 7.  Machine intelligence in non-invasive endocrine cancer diagnostics.

Authors:  Nicole M Thomasian; Ihab R Kamel; Harrison X Bai
Journal:  Nat Rev Endocrinol       Date:  2021-11-09       Impact factor: 43.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.